BioStock: BioInvent’s CMO comments on the ESMO presentation
BioInvent and Transgene presented promising phase I/IIa data on BT-001 at ESMO in Barcelona this weekend. BioStock contacted BioInvent’s CMO,…
0,915€
5,29%
Echtzeit-Aktienkurs TRANSGENE SA EO 0,50
Bid:
Ask:
Nachrichten zur TRANSGENE SA EO 0,50 Aktie
BioStock: BioInvent makes a strong entrance at ESMO in Barcelona
BioInvent has released additional positive preliminary efficacy data from its ongoing phase IIa dose expansion study of BI-1808 as a…
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops…
Availability of Transgenes 2023 Universal Registration Document
TRANSGENE (Paris: TNG) today announced that its Universal registration document for the fiscal year ended December 31, 2023, was submitted…
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based…
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
2023 Full-year results and business update …
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Strasbourg (France), Tokyo (Japan) and Waltham, Mass (USA), March 5th, 2024, 7:30 am CET - Transgene (Euronext Paris: TNG), a…
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
Strasbourg, France, January 22, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based…
Transgene S.A. reports 1H results
…
BioStock: BioInvent ready for combination studies with BT-001
BioInvent and its partner Transgene have reported positive results in the phase I/IIa study with the oncolytic virus BT-001. In…
BioInvent International: BioInvent and Transgene Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors
LUND, SE / ACCESSWIRE / May 25, 2023 / BioInvent International (STO:BINV)Treatment of all Phase 1a cohorts in monotherapy completed…
Indee Labs Partners with GenScript to Develop Direct DNA Knock-in Kit for Large Transgene Inserts
Indee Labs research collaboration with GenScript aims to develop a DNA knock-in kit for Hydropore™ to enable large transgene inserts…
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company…
Transgene S.A. reports Q3 results
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…